Replies to post #202477 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

You remind me of a statement the company made that surprised me. It deals with the skin, and, really points to how much we still don't know.

http://www.ipharminc.com/new-blog/2017/6/21/the-market-opportunity-in-atopic-dermatitis

Certain aspects of Brilacidin’s Mechanism of Action (MOA) as a defensin-mimetic may make it well-suited to treat Atopic Dermatitis (AD) (eczema) as a topical medication (formulation planning is underway), including its anti-bacterial properties as well as how it may also function to help restore balance in the skin microbiome.

As a rule, I believe most people accept the fact that antibiotics screw up with your good gut bacteria and that's why many take probiotics once treatment is completed.






In Reply to 'frrol'
With B-IBD, I wonder if such a potent G+ antibiotic in the GI tract would upset the microbiome balance and have its own knock-on (medium term) AE's. What do you think as an MD? QOL improvement is a win, no doubt, but wouldn't BP and FDA be wondering this? I suspect follow-up of such effects will be examined in the upcoming oral IBD trial, which would be super-distal. Or would this be dismissed, given the accepted use of other potent oral ABX treatments?

[baytdr]

I'm not an MD, but I have done a bit of research on this topic. Not surprisingly it rapidly gets a lot more complicated when you begin to dig into it. There is a lot of ongoing research relating to reduced diversity of the gut microbiota in IBD patients and whether it's a cause or an effect of IBD. The following link is a good place to start to understand the relationship;

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281375/

[Jhawker]

I understand your concern but I think the anti-inflammatory properties are what really help

[To infinity and beyond!]

recall prior board response to this concern you raise, a real one, the microbiome and an antibiotic in enteric formulation: it is that who knows orders of magnitude of impact with respect to the different mechanisms of action for IBD? Maybe the company will be reporting about this one day.

One simple way to ask about this: did Brilacidin IV increase C Diff colitis? This as you know is one of the current classic problems of medicine- you wreck gut microbes with systemic drugs and you get C Diff( a catastrophe in current health care)

This side effect never mentioned in the brilacidin IV studies.

Direct gut dosing with an enteric IBD application very different? Prob yes, but it remains to be seen if the antiinflammatory impact is more important at dosing that may not disrupt gut flora. O maybe the gut floraa changes will be beneficial.